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Abstract When fibroblasts are plated on a type I collagen gel
they reduce the size of the gel and the extent of collagen gel
contraction reflects the motile activity of the fibroblasts. We
found that both bovine and human lactoferrin (Lf) enhanced the
collagen gel contractile activity of WI-38 human fibroblasts. Rho
inhibitor (exoenzyme C3), Rho kinase inhibitor (Y-27632),
myosin light chain kinase inhibitor (ML-7), MEK inhibitor
(PD98059) and Src family tyrosine kinase inhibitor inhibited the
Lf-enhanced collagen gel contraction. Treatment of fibroblasts
with Lf induced the phosphorylation of myosin light chain
(MLC) within 30 min. Lf-enhanced MLC phosphorylation was
inhibited by Y-27632 and ML-7. These results suggest that Lf
promotes the motility of fibroblasts by regulating MLC
phosphorylation. ß 2001 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
A cell culture system utilizing collagen gel provides an ex-
cellent model for evaluating the e¡ects of the three-dimension-
al collagen matrix on cellular physiological properties (e.g.
organization of the cytoskeleton, regulation of signal trans-
duction pathways). When ¢broblasts are embedded or plated
on a collagen gel, they show an ability to reduce the collagen
gel surface area, and eventually they form a tissue-like struc-
ture. This phenomenon is called collagen gel contraction, and
it is considered to mimic the reorganization of the collagen
matrix that accompanies wound healing in skin [1,2]. In addi-
tion, the extent of collagen gel contraction re£ects the motility
of the ¢broblasts [1]. Both growth factors and cytokines, such
as transforming growth factor (TGF-L), platelet-derived
growth factor (PDGF), ¢broblast growth factor and lysophos-
phatidic acid (LPA) are known to promote collagen gel con-
traction by ¢broblasts [3^6].
Bovine milk and colostrum are known to be a rich source
of growth factors [7]. Reyners and coworkers reported that
bovine milk whey stimulated the wound repair activity of
myo¢broblasts [8]. In addition, Belford and coworkers re-
ported that the cell growth activity found in bovine milk
was not completely blocked by mixtures of antibodies against
known growth factors, suggesting the existence of additional
cell growth factor(s) in bovine milk and colostrum [9].
Lactoferrin (Lf) is a member of the transferrin family of
iron binding glycoproteins. Lf was ¢rst identi¢ed as an abun-
dant protein in bovine milk and colostrum. It has subse-
quently been found to be expressed in many mammalian tis-
sues and secretions [10]. Lf has a broad spectrum of
antimicrobial activity, and is thought to have a role in host
defense against microbes [10]. In addition, several studies in-
dicate that Lf acts directly on mammalian cells, resulting in
the activation of natural killer cells and neutrophils [11,12],
promotion or inhibition of epithelial cell and ¢broblast pro-
liferation [13,14], and stimulation of nerve growth factor syn-
thesis and secretion from L-M cells [15]. Interestingly, some
activities of Lf in mammalian cells are independent of its iron
binding properties [13,15]. However, the signal transduction
pathway that mediates the intracellular responses of Lf in
mammalian cells is still poorly understood.
We report here that both human Lf (hLf) and bovine Lf
(bLf) are able to enhance collagen gel contraction induced by
human ¢broblasts. To elucidate the mechanisms of Lf-induced
collagen gel contraction, we focused our study on the relation-
ship between myosin light chain (MLC) phosphorylation and
the gel contraction promoting activity of Lf.
2. Materials and methods
2.1. Cell culture
WI-38 human fetal ¢broblasts were obtained from the RIKEN Cell
Bank (Tsukuba, Japan). Cells were maintained in Dulbecco’s minimal
essential medium (DMEM) supplemented with 10% fetal bovine se-
rum (FBS) at 37‡C in a 5% CO2 atmosphere.
2.2. Materials and antibodies
Materials and chemicals were obtained as follows: puri¢ed bLf
from Nippon Protein (Tokyo, Japan); puri¢ed hLf from ICN
(Aurora, OH, USA); type I collagen solution from Nitta Gelatin
(Osaka, Japan); Rho kinase inhibitor (Y-27632) from Wel¢de Corpo-
ration (Osaka, Japan); Rho inhibitor (exoenzyme C3), myosin light
chain kinase (MLCK) inhibitor (ML-7), Src family tyrosine kinase
inhibitor (PP1) and pertussis toxin from Biomol (Plymouth Meeting,
PA, USA); MEK inhibitor (PD98059) from Wako (Osaka, Japan);
okadaic acid from Calbiochem (San Diego, CA, USA); anti-MLC
monoclonal antibody, LPA and SB203580 from Sigma (St. Louis,
MO, USA). A monoclonal antibody against phosphorylated serine
19 of MLC was a gift from Dr. Minoru Seto (Asahi Chemical Indus-
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try, Shizuoka, Japan). Iron-free bLf (apo-Lf) and iron-saturated bLf
(holo-bLf) were prepared according to procedures described by Mas-
son and Heremans [16] and Suzuki et al. [17], respectively.
2.3. Biotinylation of lactoferrin and cell surface binding assay
Biotinylation of bLf and the detection of Lf binding to WI-38 cells
was performed according to the method described by Rejman et al.
[18]. Brie£y, WI-38 cells were plated on a collagen-coated 96-well
tissue culture plate (2U104 cells/well). Cells were incubated with bio-
tinylated Lf for 4 h at 4‡C in the presence or absence of a 100-fold
molar excess of unlabeled Lf and transferrin, and with horseradish
peroxidase (HRP)-conjugated streptavidin for 1 h at room temper-
ature. The biotin^avidin complex was detected with tetramethylbenzi-
dine substrate reagent (BD PharMingen). The reaction was terminated
with 0.18 N H2SO4. Absorbance at 450 nm was read using an auto-
mated plate reader.
2.4. Collagen gel contraction assay
For a 24-well culture plate, 7 ml of cold collagen solution (3 mg/ml)
was mixed gently with 2 ml of ¢ve-fold concentrated cold DMEM.
The pH of the mixture was adjusted to 7.4 with 200 mM HEPES
containing 2.2% Na2HCO3 and then the total volume was adjusted
to 10 ml using distilled water. A 400-Wl aliquot of this collagen mix-
ture was poured into each well of the plate. Plates were allowed to
settle at 37‡C for 2 h to allow for collagen gelation. A cell suspension
containing 3.2U104 WI-38 ¢broblasts per ml was plated onto each
polymerized gel. Gel contraction was initiated by detaching the edges
of the collagen gels from the side of the wells. To document collagen
gel contraction, the gels were photographed using a charge-coupled
device camera at the indicated intervals. The collagen gel area was
quanti¢ed by NIH image software.
2.5. Wound healing assay
WI-38 cells were plated on a collagen-coated 35-mm tissue culture
dish at a density of 3.5U104 cells/cm2. Con£uent cells maintained in
serum-free DMEM for 2 days were wounded with a silicone cell
scraper with a 17-mm blade (Sumitomo Bakelite). The wounded
monolayer was rinsed with serum-free DMEM two times to remove
scratched cells and then cultured for 24 h in serum-free DMEM with
or without 1 WM Lf. The cells were ¢xed with phosphate-bu¡ered
saline (PBS) containing 3.7% formamide. Migration of the monolayer
cells into the wounded area was observed using an inverted phase-
contrast microscope (Nikon).
2.6. Western blotting
WI-38 cells were rinsed with cold PBS, and then harvested in TNE
bu¡er (20 mM Tris^HCl pH 7.4, 0.15 M NaCl, 1% Nonidet P-40,
1 mM EDTA, 5 WM L-mercaptoethanol, 1 mM phenylmethylsulfonyl
£uoride, and 10 Wg/ml aprotinin). The cell lysates were then clari¢ed
by centrifugation (15 000g, 15 min) and the supernatants (containing
10 Wg of protein) were resolved by SDS^PAGE (15% gel), and then
electrically transferred onto a nitrocellulose membrane (Schleicher and
Schuell). The membranes were then probed with primary antibodies
and further incubated with a secondary antibody conjugated with
HRP. Immunoreactivity was visualized by the enhanced chemilumi-
nescence system (Amersham Pharmacia Biotech).
3. Results
3.1. Speci¢c binding of bLf to human ¢broblasts
We examined the binding of the iron-saturated form of bLf
to WI-38 human ¢broblasts. As shown in Fig. 1A, biotinyl-
ated bLf interacted with WI-38 ¢broblasts in a saturating
manner. In the presence of a 100-fold molar excess of unla-
beled bLf, bLf binding was reduced to the background level.
bLf binding was not blocked by a 100-fold molar excess
of bovine transferrin. These observations indicate that
bovine bLf speci¢cally binds WI-38 ¢broblasts. Scatchard
analysis of the binding data resulted in a linear relationship.
The estimated association constant was 6.37U107 M31
(Fig. 1B).
3.2. Lf facilitates the collagen gel contractile activity of
human ¢broblasts
To examine the e¡ect of Lf on type I collagen gel contrac-
tion mediated by ¢broblasts, WI-38 cells were plated on type I
collagen gels as described in Section 2. bLf and hLf were
added to the culture media at a ¢nal concentration of 1 WM
at the start of collagen gel contraction. Fig. 2A shows the time
course for collagen gel contraction in the presence or absence
of hLf and bLf. Addition of both bLf and hLf enhanced the
rate of collagen gel contraction. The area of the collagen gel
was decreased by about 50% within 6 h after the initiation of
gel contraction in the presence of both bLf and hLf. On the
other hand, addition of holo-bovine transferrin (¢nal 1 WM)
did not enhance collagen gel contraction.
Lf has been demonstrated to have cell growth promoting
activity for several types of mammalian cells [13,14], and
therefore it is possible that enhanced gel contraction is caused
by an increase in the number of plated cells. We examined the
Fig. 1. Speci¢c binding of bLf to WI-38 ¢broblasts. A: WI-38 ¢bro-
blasts were incubated with increasing concentrations (0^2 WM) of
bLf in the absence (closed circle) or presence of a 100-fold molar
excess of unlabeled bLf (open circle), or bovine transferrin (open
square). The binding of biotin-labeled Lf to the WI-38 cells was de-
tected by incubation with HRP-conjugated avidin. Mean values of
three parallel measurements þ S.D. are shown. B: To determine
binding a⁄nity of bLf to WI-38 ¢broblasts, a constant concentra-
tion of biotinylated bLf (2 WM) was incubated with the cells in the
presence of increasing concentrations (0^200 WM) of unlabelled bLf.
The association constant was calculated following the procedure of
Scatchard.
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e¡ect of Lf on the growth of WI-38 ¢broblasts by quantifying
the amount of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymeth-
oxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium incorporated
into the cells. Addition of bLf and hLf (¢nal concentration
1 WM) did not increase the number of WI-38 ¢broblasts with-
in 48 h (data not shown). This result indicates that the gel
contraction promoting activity of Lf is not due to an increase
in cell number in the collagen gels.
3.3. E¡ects of apo- or holo-Lf on collagen gel contraction
Lf is known to be an iron binding protein, and some of its
functions, including its antimicrobial activity, depend upon
the iron ion [10]. We investigated the involvement of the
iron ion in the gel contraction promoting activity of Lf by
comparing the e¡ects of the iron-saturated form of bLf (holo-
Lf) and the iron-deprived form of bLf (apo-Lf) on collagen
gel contraction. We varied the concentration of these two
forms of Lf from 0.25 WM to 1.0 WM. As shown in Fig. 2B,
the e¡ect of apo-Lf on gel contraction was almost the same as
that of holo-Lf at each concentration. Furthermore, the e¡ect
of both types of Lf was dose-dependent. We conclude that the
gel contraction promoting activity of Lf is independent of the
iron ion.
3.4. Lf facilitates the motility of WI-38 ¢broblasts on collagen
It has been previously demonstrated that the extent of col-
lagen gel contraction re£ects the motile activity of the cells in
the collagen gels [1,2]. We con¢rmed the ¢broblast migration
promoting activity of Lf by using an in vitro wound healing
assay. Addition of bLf (¢nal concentration 1 WM) into serum-
free DMEM enhanced the in¢ltration of WI-38 ¢broblasts
into the wounded area within 24 h (Fig. 3C). This observation
supports the results of the collagen gel contraction assay.
3.5. Inhibition of Lf-enhanced collagen gel contraction by the
inhibitors Rho, Rock and MLCK
The small G protein Rho has been implicated in ¢broblast-
mediated collagen gel contraction and migration of ¢broblasts
[6,19]. To determine whether Rho is involved in Lf-enhanced
collagen gel contraction, we investigated the e¡ects of exoen-
zyme C3, which ADP ribosylates and inactivates Rho, on Lf-
enhanced collagen gel contraction. WI-38 cells plated on col-
lagen gels were incubated with 25 Wg/ml of exoenzyme C3 for
12 h prior to the initiation of collagen gel contraction. As
shown in Fig. 4A, exoenzyme C3 markedly blocked Lf-en-
hanced collagen gel contraction.
Rho kinase (Rock/Rok) is one of the targets of Rho and
has been implicated in the regulation of phosphorylation of
myosin light chain (MLC) and the contractile activity of ¢-
broblasts by phosphorylating, and thereby inactivating, myo-
sin light chain phosphatase [20]. To investigate whether Rock
participates in Lf-enhanced collagen gel contraction, we added
the Rock-speci¢c inhibitor Y-27632 to ¢broblast cultures. In-
cubation of ¢broblasts with Y-27632 (¢nal concentration 10
WM) attenuated Lf-enhanced collagen gel contraction (Fig.
4B). These observations indicate that Rho- and Rock-depen-
dent mechanisms are involved in Lf-enhanced collagen gel
contraction.
Recently, it was shown that the phosphorylation level of
MLC is also regulated by MLCK in ¢broblasts as well as
smooth muscle cells [20]. We investigated the e¡ects of a
MLCK inhibitor (ML-7, ¢nal concentration 3 WM) on Lf-
enhanced collagen gel contraction (Fig. 4B). Gel contraction
Fig. 2. The e¡ects of Lf on collagen gel contractile activity of WI-
38 human ¢broblasts. A: WI-38 ¢broblast suspensions (containing
3.2U105 cells) were plated on polymerized collagen gels in 24-well
plates (growth area: 200 mm2). Two hours after plating, bLf, hLf,
bovine transferrin (each 1 WM), and TGF-L (10 ng/ml) were supple-
mented into the culture media, respectively. Collagen gel contraction
was initiated by detaching the gels from the side of the wells. The
extent of gel contraction was evaluated by measuring the collagen
gel areas at 3, 6, 12 and 24 h after the initiation of collagen gel
contraction. Mean values of four parallel measurements are shown.
B: Apo-Lf or holo-Lf were supplemented into the culture media.
The concentrations of both types of Lf were increased from 0.25
WM to 1.0 WM. The collagen gel area was measured 24 h after the
initiation of collagen gel contraction. Mean values of four parallel
measurements þ S.D. are shown.
Fig. 3. Migration of ¢broblasts on collagen-coated dishes in the
presence or absence of bLf. Con£uent monolayers of WI-38 ¢bro-
blasts in collagen-coated dishes were scratched with a silicone cell
scraper as described in Section 2 (A). The cells were further main-
tained for 24 h with serum-free DMEM (B), or DMEM containing
1 WM of bLf (C). Cell migration into the wounded area was docu-
mented by photography. Each calibration bar indicates 500 Wm.
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was inhibited by ML-7; however, its e¡ect was milder than
that of the Rho/Rock inhibitors. On the other hand, pertussis
toxin (an inhibitor of the Gi class of heterotrimeric G pro-
teins) and wortmannin (a phosphatidylinositol 3-kinase inhib-
itor) had no e¡ect on Lf-enhanced collagen gel contraction
(Fig. 4B).
3.6. E¡ects of MEK/ERK cascade inhibitor and protein
tyrosine kinase inhibitor on Lf-enhanced collagen
gel contraction
Mitogen-activated protein kinase (MAPK) cascades partic-
ipate in various cellular responses to stimuli, including cell to
extracellular matrix interaction. It has been suggested that
extracellular-regulated kinase (ERK) participates in cell mi-
gration and the wound healing process [21,22]. To determine
whether MAPK cascades are involved in Lf-enhanced colla-
gen gel contraction, we examined the e¡ects of PD98059
(MEK inhibitor) and SB203580 (p38 MAPK inhibitor) on
Lf-enhanced collagen gel contractile activity of WI-38 ¢bro-
blasts. MEK is a member of the MAPK kinases and speci¢-
cally activates ERK. As shown in Fig. 4C, PD98059 (50 WM)
inhibited gel contractile activity of WI-38 ¢broblasts in the
presence or absence of bLf, suggesting that MEK/ERK cas-
cades are involved in the collagen gel contractile process. The
e¡ects of SB203580 (20 WM) were not so obvious as those of
PD98059.
The Src family protein of tyrosine kinases (PTKs) has been
implicated in activation of MAP kinase, which is induced by
cell^extracellular matrix interaction [23,24]. We next investi-
gated the e¡ects of PP1 (speci¢c inhibitor of Src family PTKs)
on Lf-enhanced collagen gel contraction. As shown in Fig.
4C, 1 WM of PP1 abrogated the gel contraction promoting
activity of bLf, suggesting that Src family PTKs are involved
in the process of Lf-enhanced collagen gel contraction. On the
other hand, okadaic acid (1 WM) did not a¡ected collagen gel
contractile activity of WI-38 cells in the presence or absence of
bLf (Fig. 4C).
3.7. Lf-induced MLC phosphorylation
To study whether the contractile activity of ¢broblasts is
associated with the phosphorylation level of MLC, we inves-
tigated the e¡ects of bLf on the phosphorylation of MLC in
WI-38 ¢broblasts using Western blotting and an antibody
against the phosphorylated serine 19 residue of MLC. As
shown in Fig. 5A, bLf (¢nal concentration 1 WM) induced
serine 19 phosphorylation of MLC within 30 min. The phos-
phorylation of MLC was sustained for 60 min following stim-
ulation. The e¡ect of hLf on MLC phosphorylation was com-
Fig. 4. E¡ects of Rho, Rock and MLCK inhibitors and MEK in-
hibitor on Lf-enhanced collagen gel contractile activity of WI-38 ¢-
broblasts. A: WI-38 ¢broblasts plated onto collagen gels in a 24-
well plate were incubated with 25 Wg/ml of exoenzyme C3 for 12 h.
The collagen gel contraction was initiated in the presence or absence
of 1 WM of bLf. Twelve hours later, the extent of gel contraction
was evaluated by measuring the area of collagen gels. Mean values
of four parallel measurements þ S.D. are shown. B,C: The e¡ects of
Y-27632 (10 WM), ML-7 (3 WM), pertussis toxin (Ptx: 25 ng/ml),
wortmannin (1 WM), PD98059 (50 WM), SB203580 (20 WM), PP1
(1 WM) and okadaic acid (1 WM) on Lf-enhanced collagen gel con-
traction. The experimental procedures were the same as in A, except
cells were incubated with the reagents for 1 h.
Fig. 5. E¡ects of Rho and MLCK inhibitors on Lf-induced MLC
phosphorylation. A: WI-38 ¢broblasts plated in collagen-coated
dishes were maintained in DMEM containing 10% FBS, and in se-
rum-free DMEM for 12 h. Subsequently, 1 WM of bLf or 10 nM of
LPA were added to the culture media. The cells were harvested at
the indicated times. The phosphorylation of MLC was detected by
Western blotting using monoclonal antibodies against phosphorylat-
ed serine 19 residue of MLC (upper panel) or total MLC (lower
panel). B: WI-38 ¢broblasts were stimulated with 1 WM of bLf in
the presence of Rho kinase inhibitor (Y-27632, 10 WM) or MLCK
inhibitor (ML-7, 3 WM). The cells were harvested 30 min following
stimulation. The phosphorylation of MLC was investigated as de-
scribed in A.
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parable to that of bLf (data not shown). To investigate the
signaling pathway responsible for Lf-enhanced MLC phos-
phorylation, we examined the e¡ect of Y-27632 and ML-7
on Lf-enhanced MLC phosphorylation. MLC phosphoryla-
tion was blocked by both Y-27632 and ML-7 (Fig. 5B). These
observations suggest that the regulation of MLC phosphory-
lation is a critical step in Lf-enhanced collagen gel contrac-
tion, and that the regulation of MLC phosphorylation is
achieved through two distinct pathways: a Rho/Rock-depen-
dent pathway and an MLCK-dependent pathway.
4. Discussion
We have shown here that both bLf and hLf have novel
activity to enhance the collagen gel contractile activity of ¢-
broblasts. Despite di¡erences in their amino acid sequence
and their patterns of glycosylation, the three-dimensional con-
formation of Lf is conserved among di¡erent mammalian spe-
cies and cells [10]. In addition, it has been shown that Lf has
the ability to interact with Lf receptors from di¡erent species
[10]. bLf was also found to speci¢cally interact with WI-38
¢broblasts. The interaction could not be inhibited by bovine
transferrin, suggesting that the e¡ects of Lf on WI-38 cells are
achieved through a receptor-mediated pathway. The Lf recep-
tor has been characterized in T-cells [25], intestinal cells [26]
and platelets [27]. In addition, the low-density lipoprotein
receptor-related protein also has a high a⁄nity for Lf
[28,29]. Based on these previous ¢ndings, identi¢cation of
the cell surface molecule responsible for Lf-enhanced collagen
gel contraction is important for further investigations into the
pathways mediating ¢broblast gel contraction.
It has been shown that the gel contractile activity of ¢bro-
blasts re£ects the motility of the cells in the gels [1,2]. We
con¢rmed the ¢broblast migration promoting activity of Lf
by using an in vitro wound healing assay (Fig. 3). It has been
shown that Lf has the ability to modulate the migration of
gastrointestinal cells and Langerhans cells [30,31]. The process
of cell migration consists of many steps, including the modu-
lation of cell adhesion and reorganization of the cytoskeleton.
It has been shown that Lf inhibits adhesion of ¢broblasts and
intestinal epithelial cells [32,33]. These observations suggest
that Lf a¡ects the migration of these cells by regulating cell
adhesion. On the other hand, we report here that MLC phos-
phorylation plays an important role in Lf-enhanced collagen
gel contraction. MLC phosphorylation is a critical step in the
formation of actin stress ¢bers, the induction of cell migration
[6,19,20], platelet aggregation [34], leukocyte phagocytosis
[35], and neurite retraction [36]. We report here that both a
Rho/Rock-dependent pathway and an MLCK-dependent
pathway contribute to Lf-enhanced MLC phosphorylation
and the collagen gel contractile activity of ¢broblasts. How-
ever, the exact mechanism through which collagen gel con-
traction is achieved is still controversial. LPA has the ability
to phosphorylate MLC, and it promotes the gel contractile
force of ¢broblasts [6]. On the other hand, LPA-induced col-
lagen gel contraction was inhibited by pertussis toxin [37].
PDGF-induced collagen gel contraction requires phosphati-
dylinositol 3-kinase activity, but this does not appear to in-
volve MLC phosphorylation [37,38]. In any case, Rho is im-
plicated in the gel contractile activity of ¢broblasts [39]. These
lines of evidence suggest that the mechanism of Lf-enhanced
collagen gel contraction is di¡erent from that of LPA and
PDGF. The mechanisms of Lf-enhanced MLC phosphoryla-
tion have yet to be elucidated.
Our experiments using the MEK inhibitor suggest that the
MEK/ERK pathway correlates with collagen gel contraction.
It was also shown that ERK was activated during collagen gel
contraction by rat mesangial cells and human ¢broblasts, and
PD98059 inhibited collagen gel contraction by mesangial cells
in serum- and agonist-free conditions [38,40,41]. On the other
hand, it was reported that PD98059 did not a¡ect gel con-
tractile activity in the presence of FBS [38], suggesting that the
MEK/ERK pathway is not involved in agonist-induced colla-
gen gel contraction. Klemke et al. reported that activated
ERK phosphorylated MLCK, and eventually enhanced
MLC phosphorylation in COS cells [21]. However, neither
PD98059 nor SB203580 inhibited Lf-enhanced MLC phos-
phorylation in WI-38 ¢broblasts (unpublished observations),
suggesting that the MEK/ERK pathway is not responsible for
Lf-enhanced MLC phosphorylation in WI-38 ¢broblasts. Fur-
ther studies are required to elucidate the role of the MEK/
ERK pathway on the process of collagen gel contraction.
It has been shown that bovine milk whey has the ability to
facilitate wound healing and gel contractile activity of dermal
¢broblasts [7]. Bovine milk and colostrum is known to be an
abundant source of cytokines and growth factors [8]. The
results of this study suggest that Lf is a major contributor
to the gel contraction promoting activity found in colostrum,
along with the other previously identi¢ed milk-derived growth
factors. Because Lf has anti-in£ammatory and antimicrobial
activity, it may be suitable for the treatment of cutaneous
wounds. However, further in vivo experiments are required
to con¢rm this.
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